Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply.
Goh KL, Chen FK, Balaratnasingam C, Abbott CJ, Hodgson LAB, Guymer RH, Wu Z. Goh KL, et al. Among authors: hodgson lab. Ophthalmology. 2022 Oct;129(10):e150-e151. doi: 10.1016/j.ophtha.2022.06.010. Epub 2022 Jul 19. Ophthalmology. 2022. PMID: 35863962 No abstract available.
Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial.
Guymer RH, Wu Z, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, McGuinness MB, Fletcher EL, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Lek JJ, Harper CA, Wickremasinghe SS, Sandhu SS, Baglin EK, Sharangan P, Braat S, Luu CD; Laser Intervention in Early Stages of Age-Related Macular Degeneration Study Group. Guymer RH, et al. Among authors: hodgson lab. Ophthalmology. 2019 Jun;126(6):829-838. doi: 10.1016/j.ophtha.2018.09.015. Epub 2018 Sep 20. Ophthalmology. 2019. PMID: 30244144 Free article. Clinical Trial.
Secondary and Exploratory Outcomes of the Subthreshold Nanosecond Laser Intervention Randomized Trial in Age-Related Macular Degeneration: A LEAD Study Report.
Wu Z, Luu CD, Hodgson LAB, Caruso E, Brassington KH, Tindill N, Aung KZ, Harper CA, Wickremasinghe SS, Sandhu SS, McGuinness MB, Chen FK, Chakravarthy U, Arnold JJ, Heriot WJ, Durkin SR, Wintergerst MWM, Gorgi Zadeh S, Schultz T, Finger RP, Cohn AC, Baglin EK, Sharangan P, Guymer RH; LEAD Study Group. Wu Z, et al. Among authors: hodgson lab. Ophthalmol Retina. 2019 Dec;3(12):1026-1034. doi: 10.1016/j.oret.2019.07.008. Epub 2019 Jul 22. Ophthalmol Retina. 2019. PMID: 31582304 Clinical Trial.
Baseline characteristics and age-related macular degeneration in participants of the "ASPirin in Reducing Events in the Elderly" (ASPREE)-AMD trial.
Robman LD, Phuong Thao LT, Guymer RH, Wolfe R, Woods RL, Hodgson LA, Phung J, Makeyeva GA, Le-Pham YA, Orchard SG, Suleiman J, Maguire E, Trevaks RE, Ward SA, Riaz M, Lacaze P, Storey E, Abhayaratna WP, Nelson MR, Ernst ME, Reid CM, McNeil JJ; ASPREE Investigator Group. Robman LD, et al. Contemp Clin Trials Commun. 2020 Oct 11;20:100667. doi: 10.1016/j.conctc.2020.100667. eCollection 2020 Dec. Contemp Clin Trials Commun. 2020. PMID: 33210016 Free PMC article.
Subthreshold Nanosecond Laser in Age-Related Macular Degeneration: Observational Extension Study of the LEAD Clinical Trial.
Guymer RH, Chen FK, Hodgson LAB, Caruso E, Harper CA, Wickremashinghe SS, Cohn AC, Sivarajah P, Tindill N, Luu CD, Wu Z; LEAD Study Group. Guymer RH, et al. Among authors: hodgson lab. Ophthalmol Retina. 2021 Dec;5(12):1196-1203. doi: 10.1016/j.oret.2021.02.015. Epub 2021 Mar 1. Ophthalmol Retina. 2021. PMID: 33662615 Clinical Trial.
70 results